ASGR1 deficiency improves atherosclerosis but alters liver metabolism in ApoE-/- mice

Abstract Abstract The asialoglycoprotein receptor 1 (ASGR1), a multivalent carbohydrate-binding receptor that primarily is responsible for recognizing and eliminating circulating glycoproteins with exposed galactose (Gal) or N-acetylgalactosamine (GalNAc) as terminal glycan residues, has been implic...

Full description

Saved in:
Bibliographic Details
Main Authors: Monika Svecla, Annalisa Moregola, Lorenzo Da Dalt, Jasmine Nour, Andrea Baragetti, Patrizia Uboldi, Alessandra Idini, Manfred Wuhrer, Giangiacomo Beretta, David Falck, Fabrizia Bonacina, Giuseppe Danilo Norata
Format: Article
Language:English
Published: BMC 2024-11-01
Series:Cardiovascular Diabetology
Subjects:
Online Access:https://doi.org/10.1186/s12933-024-02507-5
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850056001211858944
author Monika Svecla
Annalisa Moregola
Lorenzo Da Dalt
Jasmine Nour
Andrea Baragetti
Patrizia Uboldi
Alessandra Idini
Manfred Wuhrer
Giangiacomo Beretta
David Falck
Fabrizia Bonacina
Giuseppe Danilo Norata
author_facet Monika Svecla
Annalisa Moregola
Lorenzo Da Dalt
Jasmine Nour
Andrea Baragetti
Patrizia Uboldi
Alessandra Idini
Manfred Wuhrer
Giangiacomo Beretta
David Falck
Fabrizia Bonacina
Giuseppe Danilo Norata
author_sort Monika Svecla
collection DOAJ
description Abstract Abstract The asialoglycoprotein receptor 1 (ASGR1), a multivalent carbohydrate-binding receptor that primarily is responsible for recognizing and eliminating circulating glycoproteins with exposed galactose (Gal) or N-acetylgalactosamine (GalNAc) as terminal glycan residues, has been implicated in modulating the lipid metabolism and reducing cardiovascular disease burden. In this study, we investigated the impact of ASGR1 deficiency (ASGR1−/−) on atherosclerosis by evaluating its effects on plaque formation, lipid metabolism, circulating immunoinflammatory response, and circulating N-glycome under the hypercholesterolemic condition in ApoE-deficient mice. After 16 weeks of a western-type diet, ApoE−/−/ASGR1−/− mice presented lower plasma cholesterol and triglyceride levels compared to ApoE−/−. This was associated with reduced atherosclerotic plaque area and necrotic core formation. Interestingly, ApoE−/−/ASGR1−/− mice showed increased levels of circulating immune cells, increased AST/ALT ratio, and no changes in the N-glycome profile and liver morphology. The liver of ApoE−/−/ASGR1−/− mice, however, presented alterations in the metabolism of lipids, xenobiotics, and bile secretion, indicating broader alterations in liver homeostasis beyond lipids. These data suggest that improvements in circulating lipid metabolism and atherosclerosis in ASGR1 deficiency is paralleled by a deterioration of liver injury. These findings point to the need for additional evaluation before considering ASGR1 as a pharmacological target for dyslipidemia and cardiovascular disorders. Graphical abstract
format Article
id doaj-art-22aa1926ab7d4d789f5776e7cae7fd1e
institution DOAJ
issn 1475-2840
language English
publishDate 2024-11-01
publisher BMC
record_format Article
series Cardiovascular Diabetology
spelling doaj-art-22aa1926ab7d4d789f5776e7cae7fd1e2025-08-20T02:51:48ZengBMCCardiovascular Diabetology1475-28402024-11-0123111410.1186/s12933-024-02507-5ASGR1 deficiency improves atherosclerosis but alters liver metabolism in ApoE-/- miceMonika Svecla0Annalisa Moregola1Lorenzo Da Dalt2Jasmine Nour3Andrea Baragetti4Patrizia Uboldi5Alessandra Idini6Manfred Wuhrer7Giangiacomo Beretta8David Falck9Fabrizia Bonacina10Giuseppe Danilo Norata11Department of Pharmacological and Biomolecular Sciences, Università degli Studi di MilanoDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di MilanoDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di MilanoDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di MilanoDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di MilanoDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di MilanoDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di MilanoCenter for Proteomics and Metabolomics, Leiden University Medical CenterDepartment of Environmental Science and Policy, Università degli Studi di MilanoCenter for Proteomics and Metabolomics, Leiden University Medical CenterDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di MilanoDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di MilanoAbstract Abstract The asialoglycoprotein receptor 1 (ASGR1), a multivalent carbohydrate-binding receptor that primarily is responsible for recognizing and eliminating circulating glycoproteins with exposed galactose (Gal) or N-acetylgalactosamine (GalNAc) as terminal glycan residues, has been implicated in modulating the lipid metabolism and reducing cardiovascular disease burden. In this study, we investigated the impact of ASGR1 deficiency (ASGR1−/−) on atherosclerosis by evaluating its effects on plaque formation, lipid metabolism, circulating immunoinflammatory response, and circulating N-glycome under the hypercholesterolemic condition in ApoE-deficient mice. After 16 weeks of a western-type diet, ApoE−/−/ASGR1−/− mice presented lower plasma cholesterol and triglyceride levels compared to ApoE−/−. This was associated with reduced atherosclerotic plaque area and necrotic core formation. Interestingly, ApoE−/−/ASGR1−/− mice showed increased levels of circulating immune cells, increased AST/ALT ratio, and no changes in the N-glycome profile and liver morphology. The liver of ApoE−/−/ASGR1−/− mice, however, presented alterations in the metabolism of lipids, xenobiotics, and bile secretion, indicating broader alterations in liver homeostasis beyond lipids. These data suggest that improvements in circulating lipid metabolism and atherosclerosis in ASGR1 deficiency is paralleled by a deterioration of liver injury. These findings point to the need for additional evaluation before considering ASGR1 as a pharmacological target for dyslipidemia and cardiovascular disorders. Graphical abstracthttps://doi.org/10.1186/s12933-024-02507-5AtherosclerosisAsialoglycoprotein receptor 1CholesterolPlaque compositionLiver metabolism
spellingShingle Monika Svecla
Annalisa Moregola
Lorenzo Da Dalt
Jasmine Nour
Andrea Baragetti
Patrizia Uboldi
Alessandra Idini
Manfred Wuhrer
Giangiacomo Beretta
David Falck
Fabrizia Bonacina
Giuseppe Danilo Norata
ASGR1 deficiency improves atherosclerosis but alters liver metabolism in ApoE-/- mice
Cardiovascular Diabetology
Atherosclerosis
Asialoglycoprotein receptor 1
Cholesterol
Plaque composition
Liver metabolism
title ASGR1 deficiency improves atherosclerosis but alters liver metabolism in ApoE-/- mice
title_full ASGR1 deficiency improves atherosclerosis but alters liver metabolism in ApoE-/- mice
title_fullStr ASGR1 deficiency improves atherosclerosis but alters liver metabolism in ApoE-/- mice
title_full_unstemmed ASGR1 deficiency improves atherosclerosis but alters liver metabolism in ApoE-/- mice
title_short ASGR1 deficiency improves atherosclerosis but alters liver metabolism in ApoE-/- mice
title_sort asgr1 deficiency improves atherosclerosis but alters liver metabolism in apoe mice
topic Atherosclerosis
Asialoglycoprotein receptor 1
Cholesterol
Plaque composition
Liver metabolism
url https://doi.org/10.1186/s12933-024-02507-5
work_keys_str_mv AT monikasvecla asgr1deficiencyimprovesatherosclerosisbutalterslivermetabolisminapoemice
AT annalisamoregola asgr1deficiencyimprovesatherosclerosisbutalterslivermetabolisminapoemice
AT lorenzodadalt asgr1deficiencyimprovesatherosclerosisbutalterslivermetabolisminapoemice
AT jasminenour asgr1deficiencyimprovesatherosclerosisbutalterslivermetabolisminapoemice
AT andreabaragetti asgr1deficiencyimprovesatherosclerosisbutalterslivermetabolisminapoemice
AT patriziauboldi asgr1deficiencyimprovesatherosclerosisbutalterslivermetabolisminapoemice
AT alessandraidini asgr1deficiencyimprovesatherosclerosisbutalterslivermetabolisminapoemice
AT manfredwuhrer asgr1deficiencyimprovesatherosclerosisbutalterslivermetabolisminapoemice
AT giangiacomoberetta asgr1deficiencyimprovesatherosclerosisbutalterslivermetabolisminapoemice
AT davidfalck asgr1deficiencyimprovesatherosclerosisbutalterslivermetabolisminapoemice
AT fabriziabonacina asgr1deficiencyimprovesatherosclerosisbutalterslivermetabolisminapoemice
AT giuseppedanilonorata asgr1deficiencyimprovesatherosclerosisbutalterslivermetabolisminapoemice